Abstract
Background
Limited data exist regarding baseline characteristics and management of heart failure with reduced ejection fraction (EF) in tertiary care facilities.
Methods
EVITA-HF comprises web-based case report data on demography, comorbidities, diagnostic and therapy measures, quality of life, adverse events and 1-year follow-up of patients hospitalized for chronic heart failure and an ejection fraction of less than 40 %.
Results
Between February 2009 and June 2011, a total of 1,853 consecutive, hospitalized patients (pts) were included in 16 centers in Germany. Mean age was 70 years, 76 % were male. Median EF was 30 %, and 63 % were in NYHA III/IV. Ischemic cardiomyopathy was present in 56 %, history of hypertension in 76 %, diabetes in 39 %, impaired renal function in 33 %, thyroid dysfunction in 12 %, and malignoma in 7 %. Sixty-eight percent of pts had a non-elective admission. Rhythm was sinus/atrial fibrillation or flutter/pacemaker in 64, 28 and 11 %, respectively. Median heart rate amounted to 80 bpm, median blood pressure to 122/74 mmHg. LBBB was present in 26 % of non-pacemaker pts. Eighteen percent had an ICD or CRT-D. Medication (admission vs. discharge) consisted of ACEI or ARB in 73 vs. 88 %, β-blocker in 71 vs. 89 %, mineral corticosteroid receptor antagonist (MRA) in 32 vs. 57 %, diuretics in 68 vs. 83 % (p < 0.001 for each). Forty-two percent of pts received a specific treatment procedure beyond pharmacotherapy, of these 48 % revascularization, 39 % device therapy, 14 % electrical cardioversion, 5 % ablation procedures, 9 % valvular procedures, 6 % iv inotropes, 1.8 % IABP or LVAD implantation. At discharge, 33 % of survivors had ICD- or CRT-D implants. One-year mortality amounted to 16.8 %, and death or rehospitalization to 56 %. NYHA class III/IV was found in 30 % (p < 0.001 vs. index admission), general health status was improved in 45 % and unchanged in 36 % of patients. Eighty-five percent of pts took ACEI or ARB, 86 % β-blockers, 47 % MRA, and 78 % diuretics (p < 0.001 vs. index discharge for all).
Conclusion
Patients with chronic heart failure and low ejection fraction represent an elderly and multimorbid population. While hospitalized, they experience a significant optimization of prognosis-relevant medication, revascularization and device therapy. After 1 year, mortality is moderate; drug adherence is high and NYHA status favourable. The EVITA-HF registry is able to reflect coherently the real-world management, efforts and follow-up in heart failure pts managed in tertiary care facilities.
Similar content being viewed by others
References
McMurray JJV, Adamopoulos S, Anker SD et al (2012) ESC-Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. doi:10.1093/eurheartj/ehs104
Maggioni AP, Dahlstroem U, Filippatos G et al (2010) EURObservational research programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 12:1076–1084
Maggioni AP, Dahlstroem U, Filippatos G et al (2013) EURObservational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15:808–817
Cleland JG, Swedberg K, Follath F et al (2003) The EuroHeart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24:442–463
Komajda M, Follath F, Swedberg K et al (2003) The EuroHeart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24:464–474
Jonsson A, Edner M, Alehagen U et al (2010) Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 12:25–31
Oliva F, Mortara A, Cacciatore G et al (2012) Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail 14:1208–1217
Fonarow GC, Heywood JT, Heidenreich PA et al (2007) Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National registry (ADHERE). Am Heart J 153:1021–1028
Fonarow GC, Abraham WT, Albert NM et al (2008) Factors identified as precipitating hospital admissions for heart failure and clinical outcomes. Findings from Optimize-HF. Arch Intern Med 168:847–854
Yancy CW, Fonarow GC, Albert NM et al (2009) Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 157:754–762
Albert NM, Fonarow GC, Yancy CW et al (2010) Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (IMPROVE HF). Am Heart J 159:238–244
Tavazzi L, Senni M, Metra M et al (2013) Multicenter prospective observational study on acute and chronic heart failure: one year follow up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail 6:473–481
Stalhammar J, Stern L, Linder R et al (2012) Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. J Med Econ 15:938–946
Lund LH, Svennblad B, Melhus H et al (2013) Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. Circ Heart Fail 6:174–183
Choi DJ, Han S, Jeon ES et al (2011) Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the Korean heart failure registry. Korean Circ J 41:363–371
Youn YJ, Yoo BS, Lee JW et al (2012) Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure: report from the Korean Heart Failure Registry. Circ J 76:1151–1158
Parenica J, Spinar J, Vitovec J et al (2013) Long-term survival following acute heart failure: the Acute Heart Failure Database Main registry (AHEAD Main). Eur J Intern Med 24:151–160
Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M et al (2013) Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). J Cardiol 62:95–101
Sato N, Kajimoto K, Keida T et al (2013) Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77:944–951
Waldum B, Westheim AS, Sandvik L et al (2012) Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol 59:371–378
Fruhwald FM, Ulmer H, Pacher R et al (2011) Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry. Wien Klin Wochenschr 123:378–383
Fonarow GC, Abraham WT, Albert NM et al (2008) Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure). Am J Cardiol 102:1524–1529
Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO (2013) Rehospitalization for heart failure. Problems and perspectives. J Am Coll Cardiol 61:391–403
Kociol RD, Peterson ED, Hammill BG et al (2012) National survey of hospital strategies to reduce heart failure readmissions: findings from the Get with the Guidelines-Heart Failure registry. Circ Heart Fail 5:680–687
Fonarow GC (2011) Improving quality of care and outcomes for heart failure. Circ J 75:1783–1790
Chen J, Dharmarajan K, Wang Y et al (2013) National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol 61:1078–1088
Lechat P, Cibis-II Investigators (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353:9–13
Fagerberg B, Merit-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007
Pitt B, Zannad F, Remme W et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717
Packer M, Coats AJS, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658
Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237
Swedberg K, Komajda M, Boehm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376:875–885
Lenzen MJ, Boersma E, Scholte op Reimer WJM et al (2005) Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 26:2706–2713
Lee DS, Ghosh N, Floras JS et al (2009) Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail 6:616–623
Boehm M, Swedberg K, Komajda M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet 376:886–894
Frankenstein L, Katus HA, Grundtvig M et al. (2013) Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study. Eur J Clin Pharmacol [Epub]
Suarez J, Piccini JP, Liang L et al (2012) International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J 163:804–811
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
von Scheidt, W., Zugck, C., Pauschinger, M. et al. Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol 103, 1006–1014 (2014). https://doi.org/10.1007/s00392-014-0743-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-014-0743-x